13G Filing: Park West Asset Management and PLx Pharma Inc. (PLXP)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.   )*

Check the appropriate box to designate the
rule pursuant to which this Schedule 13G is filed:

[   ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[   ] Rule 13d-1(d)

* The remainder of this cover page shall be
filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

* Beneficial ownership percentage is
based upon 8,683,915 shares of common stock, $0.001 par value per share (“Common Stock”), of PLx Pharma Inc., a
Delaware corporation (the “Company”), issued and outstanding immediately after the consummation of the
Company’s public offering of Common Stock, as reported by the Company in its prospectus supplement dated June 9, 2017
(File No. 333-204830), filed with the Securities and Exchange Commission on June 12, 2017.  Park West Asset
Management LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands
exempted company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company
(“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and,
collectively with PWAM, the “Reporting Persons”) is the sole member and manager of PWAM.  As of June 9,
2017, PWIMF held 953,465 shares of Common Stock and, subject to the limitation described below, warrants to purchase up to
902,528 shares of Common Stock and PWPI held 122,258 shares of Common Stock and, subject to the limitation described below,
warrants to purchase up to 115,653 shares of Common Stock.  The warrants are not exercisable until December 15,
2017, expire on June 14, 2027, and contain a provision prohibiting exercise to the extent that the holder, together with its
affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after
giving effect to such exercise (subject to decrease upon prior written notice to the Company). As a result of the foregoing, for
purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed to beneficially own the 1,075,723 shares of Common
Stock held in the aggregate by the PW Funds, and no shares of Common Stock underlying the warrants held in the aggregate by
the PW Funds, for an aggregate beneficial ownership percentage of approximately 12.4% of the shares of Common Stock deemed
issued and outstanding as of June 9, 2017.

* Beneficial ownership percentage is based
upon 8,683,915 shares of Common Stock issued and outstanding immediately after the consummation of the Company’s public
offering of Common Stock, as reported by the Company in its prospectus supplement dated June 9, 2017 (File No. 333-204830), filed
with the Securities and Exchange Commission on June 12, 2017. As of June 9, 2017, PWIMF held 953,465 shares of Common Stock and,
subject to the limitation described below, warrants to purchase up to 902,528 shares of Common Stock. The warrants are not exercisable
until December 15, 2017, expire on June 14, 2027, and contain a provision prohibiting exercise to the extent that the holder,
together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to such exercise (subject to decrease upon prior written notice to the Company).  For purposes
of Reg. Section 240.13d-3, PWIMF may be deemed to beneficially own 953,465 shares of Common Stock, and no shares of Common Stock
underlying the warrants, for an aggregate beneficial ownership percentage of approximately 11.0% of the shares of Common Stock
deemed issued and outstanding as of June 9, 2017.

* Beneficial ownership percentage is based
upon 8,683,915 shares of Common Stock issued and outstanding immediately after the consummation of the Company’s public offering
of Common Stock, as reported by the Company in its prospectus supplement dated June 9, 2017 (File No. 333-204830), filed with the
Securities and Exchange Commission on June 12, 2017.   PWAM is the investment manager to the PW Funds, and Mr. Park is
the sole member and manager of PWAM.  As of June 9, 2017, PWIMF held 953,465 shares of Common Stock and, subject to the
limitation described below, warrants to purchase up to 902,528 shares of Common Stock and PWPI held 122,258 shares of Common Stock
and, subject to the limitation described below, warrants to purchase up to 115,653 shares of Common Stock.  The warrants are not exercisable
until December 15, 2017, expire on June 14, 2027, and contain a provision prohibiting exercise to the extent that the holder,
together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to such exercise (subject to decrease upon prior written notice to the Company). As a result of the foregoing, for purposes of Reg. Section
240.13d-3, the Reporting Persons may be deemed to beneficially own the 1,075,723 shares of Common Stock held in the aggregate by
the PW Funds, and no shares of Common Stock underlying the warrants held in the aggregate by the PW Funds, for an aggregate beneficial
ownership percentage of approximately 12.4% of the shares of Common Stock deemed issued and outstanding as of June 9, 2017.

* This Schedule
13G is being jointly filed by (i) PWAM, a Delaware limited liability company and the investment manager to (a) PWIMF, a Cayman
Islands exempted company that is the holder of 953,465 shares of Common
Stock and, subject to the limitation described below, warrants to purchase up to 902,528 shares of Common Stock, as reported on
this Schedule 13G, and (b) PWPI, a Cayman Islands exempted company that is the holder of 122,258 shares of Common Stock and, subject
to the limitation described below, warrants to purchase up to 115,653 shares of Common Stock, as reported on this Schedule 13G;
(ii) PWIMF; and and (iii) Mr. Park, as the sole member and manager of PWAM.

The
warrants held by PWIMF to purchase 902,528 shares of Common Stock and by PWPI to purchase 115,653 shares of Common
Stock are not exercisable until December 15, 2017, expire on June 14, 2027, and contain a provision prohibiting
exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number
of shares of Common Stock outstanding immediately after giving effect to such exercise (subject to decrease upon prior
written notice to the Company). As a result, for purposes of Reg. Section 240.13d-3, PWAM,
PWIMF, PWPI and Mr. Park may currently be deemed not to own any shares of Common Stock underlying the warrants.

The 1,075,723
shares of Common Stock held in the aggregate by the PW Funds, which constitutes approximately 12.4% of the shares of Common Stock
deemed issued and outstanding as of June 9, 2017, may be deemed to be beneficially owned (x) indirectly by PWAM, as the investment
adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.  The foregoing beneficial
ownership percentage is based upon 8,683,915 shares of Common Stock, issued and outstanding immediately after the consummation
of the Company’s public offering of Common Stock, as reported by the Company in its prospectus supplement dated June 9,
2017 (File No. 333-204830), filed with the Securities and Exchange Commission on June 12, 2017.

SIGNATURE

          After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Attention: Intentional misstatements or omissions
of fact constitute

Federal criminal violations (See 18 U.S.C.
1001)

Exhibit Index

Exhibit A

JOINT FILING AGREEMENT

In
accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint
filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock,
$0.001 par value per share, of PLx Pharma Inc., a Delaware corporation,
and further agree that this Joint Filing Agreement be included as Exhibit A to such Schedule 13G.  In evidence thereof,
the undersigned hereby execute this agreement this 19th day of June, 2017.